- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01599013
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (JASINT1)
Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gemcitabine and carboplatin have been the most studied and used anticancer agents in cisplatin-unfit patients with advanced urothelial carcinoma. Both agents previously demonstrated clinical activity as single agent and/or as part of combination regimen in patients with advanced or metastatic disease even if clinical benefits and survival remains limited in this setting for this population.
The purpose of this study is to test in a randomized trial enrolling patients with renal impairment or moderate congestive heart failure two combinations of a novel cytotoxic agent, vinflunine, one with gemcitabine and another with carboplatin in order to determine the most promising combination in the first line treatment of advanced/metastatic urothelial carcinoma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Boulogne, France
- Pierre Fabre Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man or woman aged ≥ 18 years and < 80 years
- Signed written informed consent
- Histologically confirmed diagnosis of locally advanced or metastatic predominantly transitional cell carcinoma of the urothelium (TCCU)
Ineligibility for cisplatin-based therapy because of at least one of the following two medical conditions:
- Calculated creatinine clearance (Cockcroft-Gault formula)< 60 mL/min
- New York Heart Association Classification Stage II-III Congestive Heart Failure (documented by medical history)
- "Measurable" disease with at least one uni-dimensional lesion according to RECIST guideline (version 1.1)
- ECOG performance status of 0 or 1
- Estimated life expectancy of at least 12 weeks
- Patient without prior systemic anticancer therapy unless if it had been administered as neoadjuvant or adjuvant chemotherapy (CT) for TCCU and if the patient has documented relapse ≥ 6 months after the last dose of CT (prior intravesical CT allowed)
Adequate bone marrow and hepatic functions as evidenced by:
- Absolute Neutrophil Count ≥ 2,000/mm3 (≥ 2.0 x 109/L)
- Haemoglobin ≥ 10 g/dL
- Platelet count ≥ 100,000/mm3
- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Transaminases ≤ 2.5 x ULN [≤ 5 x ULN only in case of liver metastasis]
- Absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions should be assessed with the patient before registration in the trial
Exclusion Criteria:
- ECOG performance status ≥ 2
- Woman if pregnant or lactating or with positive pregnancy test at inclusion; woman of child-bearing potential who did not use or is unwilling or unable to use an acceptable method to avoid pregnancy during the 2 months preceding the start of study treatment, for the entire study period and for up to 3 months after the last dose of study treatment; sexually active fertile man not using effective birth control during the study and up to 6 months after the last dose of study treatment if his partner is a woman of child-bearing potential
- Known brain metastasis or leptomeningeal involvement.
- Peripheral neuropathy Grade ≥ 2 by NCI CTC
- Prior radiation to ≥ 30% of the bone marrow or completed < 30 days ago or without full recovery of toxicities
Other serious illness or medical condition including:
- Infection requiring systemic anti-infective therapy
- Any medical condition that might not be controlled, for instance patients with unstable angina, patients with myocardial infarction within 6 months or uncontrolled diabetes
- Prior systemic chemotherapy for advanced or metastatic disease or neoadjuvant/adjuvant chemotherapy that was completed < 6 months before documented progression
- Patient who had received any other investigational drug or anti-cancer therapy within 30 days before randomisation
- Other malignancies except adequately treated basal carcinoma of the skin, in-situ cervix carcinoma, localised prostate cancer with limited risk of recurrence (pT ≤ 2b, Gleason score ≤ 7) that was incidentally discovered and did not lead to any other treatment apart from prostatectomy, or any other tumor with a disease free interval ≥ 5 years
- Inadequate renal function defined by a serum creatinine clearance < 30 mL/min (Cockcroft-Gault formula)
- Known hypersensitivity to the study drugs or to drugs with similar chemical structures
- Patients who require treatment with ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampicin (any potent CYP3A4 inhibitor or inducer) or phenytoin
- Any concurrent chronic system immune therapy or previous organ allograft
- Electrocardiogram (ECG) with significant modifications suggesting a high risk of occurrence of an acute clinical event
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Vinflunine plus Gemcitabine
|
Other Names:
|
Other: Vinflunine plus Carboplatin
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate as defined by RECIST criteria (version 1.1) as a percentage of best overall responses of Complete (CR) + Partial (PR) + Stable Disease (SD) for both Vinflunine-Gemcitabine and Vinflunine-Carboplatin combinations
Time Frame: Change from baseline in tumor assessment at 12 weeks (cycle 4)
|
Assessment of lesions (measurable and non-measurable) should be performed at baseline and every 6 weeks (assessment interval). Evaluable patients: all baseline lesions must have been assessed at least once after the second cycle (6 weeks); patients who progress before the first evaluation will be considered as early progression. Primary analysis is planned on the intent to treat population, secondary analysis being performed on the evaluable population. |
Change from baseline in tumor assessment at 12 weeks (cycle 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response Rate as defined by RECIST criteria (version 1.1) with a best response as Complete (CR) or Partial (PR)
Time Frame: Change from baseline in tumor assessment at 12 weeks (cycle 4)
|
Assessment of lesions (measurable and non-measurable) should be performed at baseline and every 6 weeks (assessment interval). Evaluable patients: all baseline lesions must have been assessed at least once after the second cycle (6 weeks); patients who progress before the first evaluation will be considered as early progression. |
Change from baseline in tumor assessment at 12 weeks (cycle 4)
|
Duration of Disease control in Participants With Best Response of CR + PR + SD
Time Frame: From the date of randomisation until the date of documented progression or date of death due to any cause, assessed up to 10 months
|
Tumor assessment at baseline and then every 6 weeks, until tumor progression.
Duration of disease control according to investigator will be calculated among the responders and stable patients from the date of randomisation until the documentation of progression or death due to any cause.
Patients who are lost to follow-up without progression, or reach the time point of analysis without a known record of progression or death will have the duration of disease control censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.
|
From the date of randomisation until the date of documented progression or date of death due to any cause, assessed up to 10 months
|
Duration of Response in Participants With Best Response of CR or PR
Time Frame: From the date that measurement criteria are first met for complete or partial response until the date of documented progression or date of death due to any cause, assessed up to 10 months
|
Tumor assessment at baseline and then every 6 weeks, until tumor progression.
Duration of response will be calculated among the responders (i.e.
CR and PR) .
Patients who are lost to follow-up, or reach the time point of analysis without a known record of progression or death will have the duration of response censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.
|
From the date that measurement criteria are first met for complete or partial response until the date of documented progression or date of death due to any cause, assessed up to 10 months
|
Time to First Response calculated among the responders
Time Frame: From the date of randomisation up to the first report of documented response, assessed up to 12 weeks (cycle 4).
|
Tumor assessment at baseline and then every 6 weeks.
Will be calculated among the responders (i.e.
CR and PR)
|
From the date of randomisation up to the first report of documented response, assessed up to 12 weeks (cycle 4).
|
Time to Treatment Failure
Time Frame: From the date of randomisation until tumor progression, unacceptable toxicity, withdrawal of patient consent, lost to follow-up or start of new anticancer therapy, assessed up to 10 months.
|
Tumor assessment (RECIST) every 6 weeks.
Patients who reach the time point of analysis without failure as defined above will have the time to treatment failure censored at the date of last tumour assessment or last contact of a follow-up not showing progression.
Patients who discontinued treatment for other reason and who are lost to follow-up will be censored at the date of last contact.
|
From the date of randomisation until tumor progression, unacceptable toxicity, withdrawal of patient consent, lost to follow-up or start of new anticancer therapy, assessed up to 10 months.
|
Progression Free Survival
Time Frame: From the date of randomisation until the date of progression or the date of death from any cause if no progression was recorded before, median patient follow-up of 11 months
|
Tumor assessment every 6 weeks (RECIST).Patients who are lost to follow-up, or reach the time point of analysis without a known record of progression or death will have the progression-free survival censored at the date of last tumour assessment or last contact of a follow-up showing no progression, whichever occur last.
|
From the date of randomisation until the date of progression or the date of death from any cause if no progression was recorded before, median patient follow-up of 11 months
|
Overall Survival
Time Frame: From the time of randomisation up to death or last follow-up, assessed with a median patient follow-up of 15 months (assessed up to 24 months)
|
Data recording every 3 months.
For patients who have not died, survival time will be censored at the date of last news (i.e: date of last administration, tumor assessment, clinical examination, haematological or biochemistrical assessment or date of last contact).
|
From the time of randomisation up to death or last follow-up, assessed with a median patient follow-up of 15 months (assessed up to 24 months)
|
Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Discontinuation
Time Frame: AE and SAE will be collected up to 30 days after the last treatment administration, on an expected average period of 17 weeks
|
Population: all treated patients unless the patient is lost to follow-up immediately after the start of the treatment. The patients will be analysed in the treatment arm they actually received. The NCI-CTC classification version 2.0 will be used to classify toxicities. Maximum grade or severity will be reported by cycle and by patient for each MedDRA Preferred Term. Analyses will be performed both regardless the relationship to treatment and related to treatment. Biochemical toxicities: the worst CTCAE version 2.0 grade will be analysed according to the grade present at baseline. |
AE and SAE will be collected up to 30 days after the last treatment administration, on an expected average period of 17 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria De Santis, MD, Center for Oncology and Hematology Kaiser Franz Josef Hospital - Vienna - Austria
- Principal Investigator: Stéphane Culine, MD, University Hospital St Louis - Paris - France
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Transitional Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Carboplatin
- Vinblastine
Other Study ID Numbers
- L00070 IN 213 P1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Transitional Cell Carcinoma Stage IV
-
European Organisation for Research and Treatment...National Cancer Institute (NCI); NCIC Clinical Trials Group; Institute of Cancer... and other collaboratorsCompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder
-
Emory UniversityTerminatedBladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the BladderUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); GlaxoSmithKlineTerminatedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the BladderUnited States
-
Association Pour La Recherche des Thérapeutiques...Roche Pharma AGCompletedRecurrent Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the BladderFrance, Belgium
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...Canada
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Bladder Carcinoma | Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Metastatic Transitional Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteJohns Hopkins University; National Cancer Institute (NCI)TerminatedRecurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on Vinflunine, Gemcitabine
-
Veeda OncologyBristol-Myers SquibbCompletedNon-Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompletedLung Cancer | Carcinoma, Small CellUnited States
-
Institute of Cancer Research, United KingdomSt George's Healthcare NHS TrustCompletedLocally-advanced or Metastatic Penile NeoplasmsUnited Kingdom
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
Bristol-Myers SquibbTerminatedStomach CancerKorea, Republic of, Philippines, Malaysia
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbPierre Fabre MedicamentCompletedKidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, BladderUnited States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
-
Bristol-Myers SquibbCompleted
-
Pierre Fabre MedicamentTerminated
-
Pierre Fabre MedicamentBristol-Myers SquibbCompletedBladder Cancer | Bladder Neoplasms | Transitional Cell Carcinoma of the Urothelial TractCanada